High dose oral amiodarone loading: electrophysiologic effects and clinical tolerance. 1992

S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles 90048.

Although amiodarone is an effective drug for the treatment of life-threatening ventricular arrhythmias, no standard oral loading dose protocol has been defined, and patients often undergo prolonged hospitalization for amiodarone loading. High dose (greater than 1,800 mg/day) oral loading has usually been reserved for unstable patients with incessant ventricular tachyarrhythmias. The current study was designed to 1) examine the clinical and electrophysiologic effects of a high dose oral amiodarone loading regimen in more stable patients; and 2) ascertain its safety and tolerance, possibly allowing shortened amiodarone loading periods and potentially decreased length of hospital stay. The study group included 16 patients with a history of recurrent ventricular arrhythmias and decreased left ventricular function, who were refractory to prior antiarrhythmic drug therapy. The oral loading protocol was 50 mg/kg per day of amiodarone for 3 days, then 30 mg/kg per day for 2 days, followed by maintenance therapy of 300 to 400 mg twice daily. Electrophysiologic testing was performed at baseline, on days 1 and 5 and during week 6. Amiodarone and desethylamiodarone levels were measured and symptoms monitored. Clinically, the high dose loading protocol was well tolerated in 15 of the 16 patients. Arrhythmias were rendered noninducible by day 1 in three patients and remained noninducible throughout the study period in two of the three. The remaining patients continued to have inducible ventricular tachycardia. Ventricular tachycardia cycle length and right ventricular effective refractory period both progressively increased significantly over baseline, starting on day 1. The 15 patients who remained in the study had no significant side effects during the loading period.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000638 Amiodarone An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. Amiobeta,Amiodarex,Amiodarona,Amiodarone Hydrochloride,Amiohexal,Aratac,Braxan,Corbionax,Cordarex,Cordarone,Kordaron,L-3428,Ortacrone,Rytmarone,SKF 33134-A,Tachydaron,Trangorex,Hydrochloride, Amiodarone,L 3428,L3428,SKF 33134 A,SKF 33134A

Related Publications

S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
January 1997, Fundamental & clinical pharmacology,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
May 1992, International journal of cardiology,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
April 1984, Journal of the American College of Cardiology,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
August 2022, CJC open,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
December 1985, Circulation,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
November 1985, The American journal of cardiology,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
December 1987, American heart journal,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
November 1983, American heart journal,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
July 1982, Chest,
S J Evans, and M Myers, and C Zaher, and J Simonson, and P Nalos, and C Vaughn, and D Oseran, and E Gang, and T Peter, and W Mandel
March 1994, Journal of the American College of Cardiology,
Copied contents to your clipboard!